Hide Board Information

Show Board Information

CymaBay Therapeutics Inc. CBAY

Board Mod: Add me as mod

Asst Mods:

Last Post: 12/15/2023 12:00:48 PM

Board Marks: 0

Posts Today: 0

Board Views Today: 7

CymaBay Therapeutics Inc. (NASDAQ: CBAY)

Company Website: http://www.cymabay.com/

CymaBay Therapeutics Inc. (NASDAQ: CBAY) Stock Message Board

1. CBAY Company Profile

    

2. CBAY Time & Sales

    

3. CBAY Recent News

    

4. CBAY Filings

    

5. CBAY Financials

    

6. CBAY Buy Rating

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

1

CBAY 8.18 Cymabay Therapeutics $CBAY stock added

clayton

12/05/2014 10:16:26 AM

Newer

Recent Articles

• Acceleware Ltd. Expands Financing Options for Growth
• Investing in Laureate Education: A 5-Year Journey to Wealth
• FDA Approves New Autoinjector for Alzheimer's Treatment
• FDA Greenlights Leqembi for Alzheimer's Maintenance Therapy
• Beijing: Blending Cultural Heritage with Modern Innovation
• Sanofi's Groundbreaking Decision for Wayrilz in the US Market
• Ocean Tides Launches Holiday Gift Wrap Multipacks on Walmart
• Understanding Knight-Swift Inc's Earnings and Market Position
• Asbestos Corporation Limited Advances Restructuring Efforts
• Rock Tech Lithium Secures $7.5 Million Investment through Offerings
• Investors Unite on Semler Scientific Securities Class Action
• Rock Tech Lithium Secures Up to $7.5 Million Fundraising
• Sword Group's 2025 Liquidity Overview with ODDO BHF
• Sanofi's Wayrilz Revolutionizes Treatment for Immune Thrombocytopenia
• Sword Group Unveils 2025 Financial Report for Investors
• Transforming $1000 Into $14,836: Ameriprise Financial's Growth
• Bravo Mining Corp. Adjusts 2024 Financial Statements After Restatement
• First Nordic Metals Reports Strong Q2 2025 Results
• Investors Prepare to Navigate Luminar Technologies Lawsuit
• Investors Stepping Forward in Spectrum Pharmaceuticals Lawsuit
• Centrus Energy Announces Participation in Key Investor Conferences
• California Energy Commission's Decision Leaves Gas Prices Unchecked
• Dr. Colleen Cowdery Strengthens Expertise at Washington Poison Center
• Immunovant Faces Investigation by Kahn Swick & Foti Law Firm
• Tamarack Resort Highlights Growth and Fire Mitigation Efforts
• Legal Inquiry into Apple Management: Key Developments Ahead
• Northland Power Reveals New Dividend Rates for Preferred Shares
• Amazing Growth: A $100 Investment in Guidewire Today
• Investors Take Action Against Semler Scientific, Inc. for Fraud
• Lundin Gold Reports Share Capital Changes and Growth Prospects
• Biomerica's Year-End Financial Review: Key Achievements and Insights
• Understanding the Semler Scientific Class Action Lawsuit Risk
• Strategic Leadership Changes at FIELDBOSS to Drive Growth
• Northland Power Unveils New Dividend Rates for Shareholders
• Anoto Group's Mid-Year Results: Key Insights and Developments
• Newcore Gold Unveils Annual Equity Incentive Awards Program
• Biomerica’s Fiscal 2025 Results: Resilient Performance Amid Challenges
• Newcore Gold's Exciting Annual Equity Incentive Award Announcement
• Understanding Shift4 Payments Inc. Financial Landscape Today
• Investing $100 in Hancock Whitney: Surprising Returns Explained
• Investing Insights: Suze Orman and Jim Cramer on Quantum Stocks
• Helium Evolution Secures $8.3 Million Funding Boost for Growth
• Patagonia Gold: Q2 2025 Financial Highlights and Future Plans
• Hyperscale Data Launches New Stock Offering Program
• Neuberger Berman High Yield Strategies Fund Announces Dividend
• Tilson Technology Management Selects Winning Bid from ITG Communications
• Eisai and Biogen Celebrate FDA Approval of LEQEMBI IQLIK Injection
• PicoCELA Inc. Faces Nasdaq Bid Price Challenge Ahead
• PicoCELA Inc. Announces Strategic Share Issuance Plans
• LEQEMBI IQLIK: A New Era in Alzheimer's Treatment Options